TACSTD2 and triple-negative breast carcinoma: For example, sacituzumab govitecan (Trodelvy®), which targets trophoblast cell-surface antigen 2 (TROP-2), has emerged as an important therapeutic option for advanced triple-negative breast cancer (21).